Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmacyclics (PCYC) -- Ignore unavailable to you. Want to Upgrade?

To: HB who wrote (241)	12/17/1997 5:54:00 PM
From: Flagrante Delictu	Read Replies (1) \| Respond to of 717

Howard, Thanks for your response. The deal with Alcon to use the PCYC technology in opthalmology indications allies us with the global leader in the research, development, manufacturing & marketing of opthalmic products including prescription drugs, contact lens care solutions , surgical instruments & accessory products, intraocular lenses & office systems for eye-care specialists & other medical offices. Alcon is a wholly owned subsidiary of Nestle S.A. Alcon currently employs nearly 9500 individuals around the world with sales in more than 200 countries & territories, according to today's press release announcing the deal. It would seem to be an encomium to have found such a strong, successful & dedicted partner which will bear all costs of worldwide development & drug registration for opthalmology indications of Lu-Tex. PCYC gets an upfront payment in addition to milestones & a royalty on product sales. The market seems to like this deal a lot better than they did the LGND-LLY deal. Bernie.